BBIO BridgeBio Pharma

BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement

BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement
EN
05/10/2020

Underlying

BBIOBridgeBio Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BridgeBio Pharma

 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascu...

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54 - Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p

March 30, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with L...

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function - Based on ongoing discussions with the FDA, BridgeBio anticipates approval with a U.S. launch anticipated in late 2026/early 2027 - If approved, BBP-418 has the potential to become the first and only therapy for individuals living with LGMD2I/R9 and may ...

March 30, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRi...

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that long-term efficacy and safety data in patients with ATTR-CM from the open-label extension (OLE) trial of ATTRibute-CM, its Phase 3 study of acoramidis, will be shared in a late-breaking oral presentation at the American College of Cardiolog...

March 23, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on March 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 29 new employees in restricted stock units for an aggregate of 70,916 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock uni...

March 20, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile ...

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 - Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups - Early separation from placebo observed in 100MTT, with improvements in ambulation evident as early as three months following initiation of BBP-418 treatment - Based on the positive interim analysis results, BridgeBio intends to submit an NDA to the FDA for traditio...

March 11, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch